Progression and survival of MBL: a screening study of 10 139 individuals

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Nicholas J. Boddicker, Janet E. Olson, Geffen Kleinstern, Connie E. Lesnick, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt

Research output: Contribution to journalArticlepeer-review

Abstract

Monoclonal B-cell lymphocytosis (MBL) is a common hematological premalignant condition that is understudied in screening cohorts. MBL can be classified into low-count (LC) and high-count (HC) types based on the size of the B-cell clone. Using the Mayo Clinic Biobank, we screened for MBL and evaluated its association with future hematologic malignancy and overall survival (OS). We had a two-stage study design including discovery and validation cohorts. We screened for MBL using an eight-color flow-cytometry assay. Medical records were abstracted for hematological cancers and death. We used Cox regression to evaluate associations and estimate hazard ratios and 95% confidence intervals (CIs), adjusting for age and sex. We identified 1712 (17%) individuals with MBL (95% LC-MBL), and the median follow-up time for OS was 34.4 months with 621 individuals who died. We did not observe an association with OS among individuals with LC-MBL (P = .78) but did among HC-MBL (hazard ratio, 1.8; 95% CI, 1.1-3.1; P = .03). Among the discovery cohort with a median of 10.0 years follow-up, 31 individuals developed hematological cancers with two-thirds being lymphoid malignancies. MBL was associated with 3.6-fold risk of hematological cancer compared to controls (95% CI, 1.7-7.7; P < .001) and 7.7-fold increased risk for lymphoid malignancies (95% CI:3.1-19.2; P < .001). LC-MBL was associated with 4.3-fold risk of lymphoid malignancies (95% CI, 1.4-12.7; P = .009); HC-MBL had a 74-fold increased risk (95% CI, 22-246; P < .001). In this large screening cohort, we observed similar survival among individuals with and without LC-MBL, yet individuals with LC-MBL have a fourfold increased risk of lymphoid malignancies. Accumulating evidence indicates that there are clinical consequences to LC-MBL, a condition that affects 8 to 10 million adults in the United States.

Original languageEnglish
Pages (from-to)1702-1709
Number of pages8
JournalBlood
Volume140
Issue number15
DOIs
StatePublished - 13 Oct 2022

Bibliographical note

Funding Information:
The authors thank the individuals from the Mayo Clinic Biobank for their contributions and continuing participation. This work would not be done without their valuable time and effort. This work was supported by the National Institutes of Health (NIH), National Institute on Aging grant R01 AG58266 and NIH National Cancer Institute grants R01 CA200703, and P50 CA097274. The Mayo Clinic Center for Individualized Medicine provided the Mayo Clinic Biobank materials.

Funding Information:
The authors thank the individuals from the Mayo Clinic Biobank for their contributions and continuing participation. This work would not be done without their valuable time and effort. This work was supported by the National Institutes of Health (NIH), National Institute on Aging grant R01 AG58266 and NIH National Cancer Institute grants R01 CA200703 , and P50 CA097274 . The Mayo Clinic Center for Individualized Medicine provided the Mayo Clinic Biobank materials.

Publisher Copyright:
© 2022 American Society of Hematology

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Progression and survival of MBL: a screening study of 10 139 individuals'. Together they form a unique fingerprint.

Cite this